Skip to main content

Advertisement

Log in

Evaluation of Circulating YKL-40 Levels in Idiopathic Interstitial Pneumonias

  • Published:
Lung Aims and scope Submit manuscript

Abstract

Introduction

YKL-40 is a novel biomarker in diseases with inflammation, fibrosis and tissue remodelling. Previously, circulating YKL-40 was shown to be elevated in patients with idiopathic pulmonary fibrosis (IPF) and was associated with survival.

Objective

To compare YKL-40 serum levels between IPF and other interstitial pneumonias such as non-specific interstitial pneumonia (NSIP), smoking-related interstitial lung disease (SR-ILD) and cryptogenic organising pneumonia (COP).

Materials and Methods

Serum YKL-40 levels were measured in 124 healthy controls and 315 patients. Serial measurements were available in 36 patients with IPF and 6 patients with COP.

Results

Serum YKL-40 levels were elevated in all patient groups compared to controls (p < 0.0001), and highest levels were found in the most fibrotic diseases, which showed worst prognosis.

Conclusion

YKL-40 is highly elevated in fibrotic interstitial pneumonias and may reflect the degree of activity of the fibrogenic process. Remarkably, levels remain high in IPF, but can decrease in other interstitial pneumonias, which appears to be related to a better prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. ATS/ERS statement. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277–304

  2. Korthagen NM, van Moorsel CH, Barlo NP et al (2011) Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med 105:106–113

    Article  PubMed  Google Scholar 

  3. Furuhashi K, Suda T, Nakamura Y et al (2010) Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med 104:1204–1210

  4. Bleau G, Massicotte F, Merlen Y, Boisvert C (1999) Mammalian chitinase-like proteins. EXS 87:211–221

    CAS  PubMed  Google Scholar 

  5. Ling H, Recklies AD (2004) The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 380:651–659

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Rathcke CN, Johansen JS, Vestergaard H (2006) YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 55:53–59

    Article  CAS  PubMed  Google Scholar 

  7. Volck B, Price PA, Johansen JS et al (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110:351–360

    CAS  PubMed  Google Scholar 

  8. Bigg HF, Wait R, Rowan AD, Cawston TE (2006) The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem 281:21082–21095

    Article  CAS  PubMed  Google Scholar 

  9. Johansen JS (2006) Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 53:172–209

    CAS  PubMed  Google Scholar 

  10. Johansen JS, Christoffersen P, Moller S et al (2000) Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 32:911–920

    Article  CAS  PubMed  Google Scholar 

  11. Erzin Y, Uzun H, Karatas A, Celik AF (2008) Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn’s disease. J Gastroenterol Hepatol 23:e357–e362

    Article  CAS  PubMed  Google Scholar 

  12. Kruit A, Grutters JC, Ruven HJ, van Moorsel CC, van den Bosch JM (2007) A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker. Respir Med 101:1563–1571

    Article  PubMed  Google Scholar 

  13. Parra ER, Noleto GS, Tinoco LJ, Capelozzi VL (2008) Immunophenotyping and remodeling process in small airways of idiopathic interstitial pneumonias: functional and prognostic significance. Clin Respir J 2:227–238

    Article  CAS  PubMed  Google Scholar 

  14. Suda T, Kono M, Nakamura Y et al (2010) Distinct prognosis of idiopathic nonspecific interstitial pneumonia (NSIP) fulfilling criteria for undifferentiated connective tissue disease (UCTD). Respir Med 104:1527–1534

    Article  PubMed  Google Scholar 

  15. Kunz L (2011) ‘t Wout E, van Schadewijk A, and Hiemstra P. YKL-40: Novel marker for pro-inflammatory M1 macrophages. Eur Respir J 38:3861

    Google Scholar 

  16. Matsumoto T, Tsurumoto T (2001) Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters. Clin Exp Rheumatol 19:655–660

    CAS  PubMed  Google Scholar 

  17. Johansen JS, Baslund B, Garbarsch C et al (1999) YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum 42:2624–2630

    Article  CAS  PubMed  Google Scholar 

  18. Recklies AD, White C, Ling H (2002) The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 365:119–126

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Letuve S, Kozhich A, Arouche N et al (2008) YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 181:5167–5173

    Article  CAS  PubMed  Google Scholar 

  20. Domagala-Kulawik J (2008) BAL in the diagnosis of smoking-related interstitial lung diseases: review of literature and analysis of our experience. Diagn Cytopathol 36:909–915

    Article  PubMed  Google Scholar 

  21. Pechkovsky DV, Prasse A, Kollert F et al (2010) Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin Immunol 137:89–101

    Article  CAS  PubMed  Google Scholar 

  22. Song JW, Hong SB, Lim CM, Koh Y, Kim DS (2011) Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37:356–363

    Article  CAS  PubMed  Google Scholar 

  23. Daniels CE, Yi ES, Ryu JH (2008) Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J 32:170–174

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jan C. Grutters.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Korthagen, N.M., van Moorsel, C.H.M., Zanen, P. et al. Evaluation of Circulating YKL-40 Levels in Idiopathic Interstitial Pneumonias. Lung 192, 975–980 (2014). https://doi.org/10.1007/s00408-014-9647-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-014-9647-9

Keywords

Navigation